Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – SunTrust Banks reduced their Q3 2017 earnings per share (EPS) estimates for shares of Zimmer Biomet Holdings in a research note issued on Friday. SunTrust Banks analyst B. Nudell now anticipates that the medical equipment provider will earn $1.77 per share for the quarter, down from their prior estimate of $1.96. SunTrust Banks also issued estimates for Zimmer Biomet Holdings’ Q4 2017 earnings at $2.26 EPS and Q2 2018 earnings at $2.17 EPS.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the consensus estimate of $2.10 by $0.02. The firm had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The company’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.02 earnings per share.

COPYRIGHT VIOLATION WARNING: This story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/07/suntrust-banks-research-analysts-cut-earnings-estimates-for-zimmer-biomet-holdings-inc-nysezbh.html.

ZBH has been the topic of a number of other research reports. Stifel Nicolaus reissued a “hold” rating and issued a $125.00 target price on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Needham & Company LLC boosted their target price on Zimmer Biomet Holdings from $151.00 to $153.00 and gave the company a “strong-buy” rating in a research report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 target price on Zimmer Biomet Holdings and gave the company a “buy” rating in a research report on Friday, April 28th. BMO Capital Markets reaffirmed a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet Holdings in a research report on Tuesday, July 11th. Finally, Wells Fargo & Company reaffirmed a “market weight” rating on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $137.76.

Zimmer Biomet Holdings (NYSE:ZBH) opened at 117.93 on Monday. Zimmer Biomet Holdings has a 12-month low of $95.63 and a 12-month high of $133.49. The stock has a market capitalization of $23.80 billion, a P/E ratio of 33.59 and a beta of 1.20. The firm’s 50-day moving average price is $127.65 and its 200 day moving average price is $121.39.

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 28th. Shareholders of record on Friday, June 23rd were paid a $0.24 dividend. The ex-dividend date of this dividend was Wednesday, June 21st. This represents a $0.96 annualized dividend and a yield of 0.81%. Zimmer Biomet Holdings’s dividend payout ratio is presently 27.59%.

In other Zimmer Biomet Holdings news, insider Sang Yi sold 17,731 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Tony W. Collins sold 16,986 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The disclosure for this sale can be found here. Corporate insiders own 1.07% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust increased its position in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares in the last quarter. Parallel Advisors LLC increased its position in Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares in the last quarter. IHT Wealth Management LLC increased its position in Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares in the last quarter. Sandy Spring Bank increased its position in Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 20 shares in the last quarter. Finally, Penserra Capital Management LLC increased its position in Zimmer Biomet Holdings by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,288 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 112 shares in the last quarter. Institutional investors own 84.13% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Earnings History and Estimates for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.